



201 Technology Drive • Irvine • California • 92618  
Telephone: (949) 450-5400  
Facsimile: (949) 450-5300  
Email: [IR@endocare.com](mailto:IR@endocare.com)  
Website: [www.endocare.com](http://www.endocare.com)

FOR RELEASE October 25, 2007 at 6:00 am EDT

Investor Contact:

Matt Clawson  
Allen & Caron, Inc.  
(949) 474-4300  
[matt@allencaron.com](mailto:matt@allencaron.com)

Media Contact:

Len Hall  
Allen & Caron, Inc.  
(949) 474-4300  
[len@allencaron.com](mailto:len@allencaron.com)

For Additional Information:

Craig T. Davenport, CEO  
Michael R. Rodriguez, CFO  
Endocare, Inc.  
(949) 450-5400

**NEW STUDY DATA PUBLISHED IN *BRITISH JOURNAL OF UROLOGY*  
DEMONSTRATES CRYOABLATION EFFECTIVE FOR KIDNEY CANCER**

*78 Patients Take Part in Five-Year, Retrospective University of Wisconsin Study*

IRVINE, CA (October 25, 2007) . . . Endocare, Inc. (NASDAQ: ENDO), an innovative medical device company focused on the development of minimally invasive technologies used by urologists and interventional radiologists for tissue and tumor ablation, announced today that a new five-year retrospective study published in the October issue of the *British Journal of Urology* demonstrates that cryoablation is an effective treatment for patients with small kidney tumors.

A total of 78 patients who had 88 small tumors (mean tumor size was 2.6 cm in diameter) took part in the study led by Stephen Y. Nakada, M.D., of the Division of Urology at the University of Wisconsin, Madison. The cancerous lesions were ablated through either laparoscopic or percutaneous cryoablation in one operative procedure in 95 percent of the cases and, after a mean follow-up of 19 months, the cancer-specific survival rate was 100 percent and recurrence-free survival rate was 98.7 percent.

Dr. Nakada and the researchers noted that the collaboration between urologists and radiologists is optimal for these patients to best target and guide the ablations. He added that cryoablation was most appropriate for kidney tumors 4 cm or less in diameter.

Craig T. Davenport, President, CEO and Chairman of Endocare, said that “Dr. Nakada’s five-year experience is providing additional confirmation and results that support the growing body of academic research that cryoablation treatment for kidney tumors is effective. The results from Dr. Nakada and his colleagues at the University of Wisconsin are quite impressive and we are pleased to see these results receiving recognition in journals like the *British Journal of Urology*.”

Cryoablation is a minimally-invasive and non-surgical therapy that uses the Endocare Cryocare Surgical System® to precisely target, freeze and destroy cancerous tissue.

**About Endocare**

Endocare, Inc.—[www.endocare.com](http://www.endocare.com)— is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver and palliative intervention (treatment of pain associated with metastases).

*Statements contained in this release that are not historical facts are forward-looking statements that involve risks and uncertainties. Among the important factors which could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, those discussed in “Risk Factors” in the Company’s Forms 10-K, Forms 10-Q, and other filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. The Company undertakes no obligation to revise, or update publicly, any forward-looking statements for any reason.*

###